Cost-effectiveness and equity impacts of three HPV vaccination programmes for school-aged girls in New Zealand

Vaccine

Volumn 32, Issue 22, 2014, Pages 2645-2656

  Blakely, Tony ^a   Kvizhinadze, Giorgi ^a   Karvonen, Tanja ^b   Pearson, Amber L ^a   Smith, Megan ^c   Wilson, Nick ^a  

^a UNIVERSITY OF OTAGO   (New Zealand)

^b UNIVERSITY OF YORK   (United Kingdom)

^c UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

Anogenital warts; Cervical cancer; Cost effectiveness; Cost utility analysis; Equity; HPV vaccination; Markov model; Meori health

Indexed keywords

WART VIRUS VACCINE;

ANUS CANCER; ARTICLE; CHILD; CONDYLOMA ACUMINATUM; COST EFFECTIVENESS ANALYSIS; FEMALE; HEALTH CARE COST; HEALTH STATUS; HERD IMMUNITY; HUMAN; MAJOR CLINICAL STUDY; MALE; OROPHARYNX CANCER; PRECANCER; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; UTERINE CERVIX CANCER; VACCINATION; VULVA CANCER;

ANOGENITAL WARTS; CERVICAL CANCER; COST-EFFECTIVENESS; COST-UTILITY ANALYSIS; EQUITY; HPV VACCINATION; MARKOV MODEL; MĀORI HEALTH;

CHILD; COST-BENEFIT ANALYSIS; ETHNIC GROUPS; FEMALE; HEALTH CARE COSTS; HUMANS; MANDATORY PROGRAMS; MARKOV CHAINS; MASS VACCINATION; MODELS, ECONOMIC; MONTE CARLO METHOD; NEW ZEALAND; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; QUALITY-ADJUSTED LIFE YEARS; UTERINE CERVICAL NEOPLASMS;

EID: 84898547431     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2014.02.071     Document Type: Article

References (43)

1. Seto K., Marra F., Raymakers A., Marra C.A. The cost effectiveness of human papillomavirus vaccines: a systematic review. Drugs 2012, 72:715-743.
2. Canfell K., Chesson H., Kulasingam S.L., Berkhof J., Diaz M., Kim J.J. Modeling preventative strategies against human papillomavirus-related disease in developed countries. Vaccine 2012, 30(Suppl. 5):F157-F167.
3. Smith M.A., Lew J.B., Walker R.J., Brotherton J.M., Nickson C., Canfell K. The predicted impact of HPV vaccination on male infections and male HPV-related cancers in Australia. Vaccine 2011, 29:9112-9122.
4. Horn J., Damm O., Kretzschmar M.E., Delere Y., Wichmann O., Kaufmann A.M., et al. Estimating the long-term effects of HPV vaccination in Germany. Vaccine 2013, 31:2372-2380.
5. Canfell K. Models of cervical screening in the era of human papillomavirus vaccination. Sex Health 2010, 7:359-367.
6. Sopina E., Ashton T. Cost-effectiveness of a cervical screening program with human papillomavirus vaccine. Int J Technol Assess Health Care 2011, 27:290-297.
7. Coupe V.M., Bogaards J.A., Meijer C.J., Berkhof J. Impact of vaccine protection against multiple HPV types on the cost-effectiveness of cervical screening. Vaccine 2012, 30:1813-1822.
8. Lee L.A., Franzel L., Atwell J., Datta S.D., Friberg I.K., Goldie S.J., et al. The estimated mortality impact of vaccinations forecast to be administered during 2011-2020 in 73 countries supported by the GAVI Alliance. Vaccine 2013, 31(Suppl. 2):B61-B72.
9. McDougall J.A., Madeleine M.M., Daling J.R., Li C.I. Racial and ethnic disparities in cervical cancer incidence rates in the United States, 1992-2003. Cancer Causes Control 2007, 18:1175-1186.
10. Parikh S., Brennan P., Boffetta P. Meta-analysis of social inequality and the risk of cervical cancer. Int J Cancer 2003, 105:687-691.
11. Shack L., Jordan C., Thomson C.S., Mak V., Moller H. Variation in incidence of breast, lung and cervical cancer and malignant melanoma of skin by socioeconomic group in England. BMC Cancer 2008, 8:271. UKAoC Registries.
12. Blakely T., Shaw C., Atkinson J., Cunningham R., Sarfati D. Social inequalities or inequities in cancer incidence? Repeated census-cancer cohort studies, New Zealand 1981-1986 to 2001-2004. Cancer Causes Control 2011, 22:1307-1318.
13. Jemal A., Simard E.P., Dorell C., Noone A.M., Markowitz L.E., Kohler B., et al. Annual Report to the Nation on the Status of Cancer, 1975-2009, featuring the burden and trends in human papillomavirus(HPV)-associated cancers and HPV vaccination coverage levels. J Natl Cancer Inst 2013, 105:175-201.
14. Brisson M., Drolet M., Malagon T. Inequalities in Human Papillomavirus (HPV)-associated cancers: implications for the success of HPV vaccination. J Natl Cancer Inst 2013, 105:158-161.
15. Malagon T., Joumier V., Boily M.C., Van de Velde N., Drolet M., Brisson M. The impact of differential uptake of HPV vaccine by sexual risks on health inequalities: a model-based analysis. Vaccine 2013, 31:1740-1747.
16. Turner N. HPV vaccination coverage in New Zealand: closing the equity gap. HPV Today 2011, 23.
17. Brisson M., van de Velde N., Franco E.L., Drolet M., Boily M.C. Incremental impact of adding boys to current human papillomavirus vaccination programs: role of herd immunity. J Infect Dis 2011, 204:372-376.
18. Chesson H.W., Ekwueme D.U., Saraiya M., Dunne E.F., Markowitz L.E. The cost-effectiveness of male HPV vaccination in the United States. Vaccine 2011, 29:8443-8450.
19. Gertig D., Brotherton J., Saville M. Measuring human papillomavirus (HPV) vaccination coverage and the role of the National HPV Vaccination Program Register, Australia. Sex Health 2011, 8:171-178.
20. 3 Team, Department of Public Health, University of Otago, Wellington.
21. Blakely T., Costilla R., Soeberg M. Cancer excess mortality rates over 2006-2026 for ABC-CBA. Burden of Disease Epidemiology, Equity and Cost-Effectiveness Programme - technical report No. 10 2012, Department of Public Health, University of Otago, Wellington.
22. Salomon J.A., Vos T., Hogan D.R., Gagnon M., Naghavi M., Mokdad A., et al. Common values in assessing health outcomes from disease and injury: disability weights measurement study for the Global Burden of Disease Study 2010. Lancet 2012, 380:2129-2143.
23. Wilson N., Nghiem N., Foster R., Cobiac L., Blakely T. Estimating the cost of new public health legislation. Bull World Health Organ 2012, 90:532-539.
24. Ali H., Donovan B., Wand H., Read T.R.H., Regan D.G., Grulich A.E., et al. Genital warts in young Australians five years into national human papillomavirus vaccination programme: national surveillance data. BMJ 2013, 346:f2032.
25. Dobson S.M., McNeil S., Dionne M., Dawar M., Ogilive G., Krajden M., et al. Immunogenicity of 2 doses of HPV vaccine in younger adolescents vs 3 doses in young women: a randomized clinical trial. JAMA 2013, 309:1793-1802.
26. Soeberg M., Blakely T., Sarfati D., Tobias M., Costilla R., Carter K., et al. CancerTrends: trends in cancer survival by ethnic and socioeconomic group, New Zealand 1991-2004 2012, University of Otago and Ministry of Health, Wellington.
27. Kulasingam S., Connelly L., Conway E., Hocking J.S., Myers E., Regan D.G., et al. A cost-effectiveness analysis of adding a human papillomavirus vaccine to the Australian National Cervical Cancer Screening Program. Sex Health 2007, 4:165-175.
28. Chesson H.W., Forhan S.E., Gottlieb S.L., Markowitz L.E. The potential health and economic benefits of preventing recurrent respiratory papillomatosis through quadrivalent human papillomavirus vaccination. Vaccine 2008, 26:4513-4518.
29. Ministry of Health Our children's health: key findings on the health of New Zealand children 1998, Ministry of Health, Wellington.
30. Canfell K., Lew J.B., Clements M., Smith M., Harris J., Simonella L., et al. Impact of HPV vaccination on cost-effectiveness of existing screening programs: example from New Zealand. 28th international human papillomavirus conference & clinical and public health workshops 2012.
31. Kahn Ja B.D.I. Hpv vaccination: too soon for 2 doses?. JAMA 2013, 309:1832-1834.
32. 3) - technical report No. 4 2011, Department of Public Health, University of Otago, Wellington.
33. Costilla R., Atkinson J., Blakely T. Incorporating ethnic and deprivation variation to cancer incidence estimates over 2006-2026 for ABC-CBA. Burden of Disease Epidemiology, Equity and Cost-Effectiveness Programme - technical report No. 5 2011, Department of Public Health, University of Otago, Wellington.
34. Smith M., Walker R., Canfell K. National cervical screening programme monitoring report No. 34: 1 July-31 December 2010 2012, National Screening Unit, Ministry of Health, Wellington.
35. Brotherton J.M. How much cervical cancer in Australia is vaccine preventable? A meta-analysis. Vaccine 2008, 26:250-256.
36. Clifford G., Franceschi S. Members of the human papillomavirus type 18 family (alpha-7 species) share a common association with adenocarcinoma of the cervix. Int J Cancer J Int Cancer 2008, 122:1684-1685.
37. Watson M., Saraiya M., Ahmed F., Cardinez C.J., Reichman M.E., Weir H.K., et al. Using population-based cancer registry data to assess the burden of human papillomavirus-associated cancers in the United States: overview of methods. Cancer 2008, 113:2841-2854.
38. Brestovac B., Harnett G.B., Smith D.W., Shellam G.R., Frost F.A. Human papillomavirus genotypes and their association with cervical neoplasia in a cohort of Western Australian women. J Med Virol 2005, 76:106-110.
39. Clifford G.M., Smith J.S., Plummer M., Munoz N., Franceschi S. Human papillomavirus types in invasive cervical cancer worldwide: a meta-analysis. Br J Cancer 2003, 88:63-73.
40. Stevens M., Tabrizi S., Quinn M., Garland S. Human papillomavirus genotype prevalence in cervical biopsies from women diagnosed with cervical intraepithelial neoplasia or cervical cancer in Melbourne, Australia. Int J Gynecol Cancer 2006, 16:1017-1024.
41. Kvizhinadze G., Blakely T. Projected NZ life tables. Burden of Disease Epidemiology, Equity and Cost-Effectiveness Programme - technical report No. 4 2011, Department of Public Health, University of Otago, Wellington.
42. Jeffreys M., Rachet B., McDowell S., Habib A.G., Lepage C., Coleman M.P. Survival from rectal and anal cancers in England and Wales, 1986-2001. Eur J Cancer 2006, 42:1434-1440.
43. Klint A., Tryggvadottir L., Bray F., Gislum M., Hakulinen T., Storm H.H., et al. Trends in the survival of patients diagnosed with cancer in female genital organs in the Nordic countries 1964-2003 followed up to the end of 2006. Acta Oncol 2010, 49:632-643.